IMPL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 des 2023 @ 21:58):

Stats
Dagens volum	720 030
Gjennomsnittsvolum	1.02M
Markedsverdi	956 000
EPS	$0 ( 2024-03-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0128
ATR14	$0.116 (114.74%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Smith Brandon D	Buy	0
2023-12-15	Vivo Capital Viii, Llc	Sell	87 934	Common Stock
2023-12-18	Vivo Capital Viii, Llc	Sell	209 029	Common Stock
2023-12-19	Vivo Capital Viii, Llc	Sell	208 657	Common Stock
2023-12-15	Vivo Capital Viii, Llc	Sell	12 066	Common Stock

INSIDER POWER
47.38
Last 95 transactions
Buy: 8 739 782 \| Sell: 5 181 184

Volum Korrelasjon

Lang: 0.42 (neutral)

Kort: -0.39 (neutral)

Signal:(41.758) Neutral

Impel Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
FNWB	0.921
EGBN	0.909
CNSL	0.904
DIBS	0.901
ALTO	0.896
FTXO	0.892
FFIC	0.885
FRST	0.883
CSTE	0.881
CCSI	0.88

10 Mest negative korrelasjoner
LMNR	-0.937
WIRE	-0.927
NRDS	-0.918
MHUA	-0.893
PEGA	-0.892
SKYT	-0.889
OBT	-0.889
MORF	-0.886
HTBI	-0.884
HUGE	-0.882

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Impel Pharmaceuticals Korrelasjon - Valuta/Råvare

0.45
( neutral )

0.62
( weak )

0.00
( neutral )

0.64
( weak )

0.21
( neutral )

-0.57
( weak negative )

Impel Pharmaceuticals Økonomi

Annual	2022
Omsetning:	$12.65M
Bruttogevinst:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2022
Omsetning:	$12.65M
Bruttogevinst:	$6.16M (48.66 %)
EPS:	$-5.52

FY	2021
Omsetning:	$668 000
Bruttogevinst:	$-23 000.00 (-3.44 %)
EPS:	$-5.25

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Impel Pharmaceuticals

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.